RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Clinical trials for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GLIOBLASTOMA, IDH-WILDTYPE trials appear
Sign up with your email to follow new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Fat stem cells injected into brain during surgery to fight returning tumors
Disease control Recruiting nowThis early-stage trial tests whether stem cells taken from body fat and placed directly into the brain during surgery can help treat glioblastoma that has come back. About 20 adults with recurrent glioblastoma or a related brain cancer will receive the stem cells. The main goal i…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 09:05 UTC
-
New hope for recurrent brain cancer? drug duo enters early testing
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs, triapine and temozolomide, in about 30 adults whose glioblastoma (a type of brain cancer) has come back. The main goal is to find the safest dose and understand side effects. The drugs work by damaging cancer cells' DNA to …
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 26, 2026 09:02 UTC
-
New combo therapy targets deadly brain tumor recurrence
Disease control Recruiting nowThis early-stage trial tests a combination of two immunotherapies (D2C7-IT and 2141-V11) for people with recurrent glioblastoma, a fast-growing brain cancer. The treatment is delivered directly into the tumor area after surgery, followed by injections near the neck. The goal is t…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: Darell Bigner • Aim: Disease control
Last updated May 26, 2026 08:55 UTC
-
Engineered immune cells take on deadly brain tumors in new trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called P134 cells for people whose glioblastoma brain cancer has come back. The treatment uses the patient's own immune cells, modified to target two markers on the cancer cells. The study aims to find the safest dose and see if it can…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug combo takes on deadly brain tumor
Disease control Recruiting nowThis study tests two immunotherapy drugs, efineptakin alfa and pembrolizumab, in people whose glioblastoma has returned after standard treatment. The goal is to see if this combination can help the immune system fight the tumor and improve survival. About 54 adults with recurrent…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for recurrent brain cancer? drug combo trial launches
Disease control Recruiting nowThis study tests a new drug (selinexor) added to standard chemotherapy (temozolomide) for people with glioblastoma that has returned after initial treatment. The goal is to see if the combination is safe and works better than chemotherapy alone to shrink or stabilize the tumor. A…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Engineered immune cells target deadly brain tumors in new trial
Disease control Recruiting nowThis early-stage trial tests a new treatment for adults with high-grade gliomas that have returned or worsened. The therapy uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells, and delivers them directly into the brain. The main goals are to…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New hope for aggressive brain tumors: drug combo shows promise before surgery
Disease control Recruiting nowThis study tests two drugs, GI-102 and pembrolizumab, given before surgery to people whose aggressive brain cancer (glioblastoma) has returned. The goal is to see if these drugs can shrink the tumor and help the immune system fight the cancer. About 36 adults will take part, and …
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC